Ki67表达与乳腺癌新辅助化疗疗效的关系(1)
[摘要] 目的 探讨Ki67表达与乳腺癌新辅助化疗疗效的关系。 方法 选取本院2010年1月～2014年1月收治入院的接受新辅助化疗的乳腺癌患者80例，根据Ki67的阳性细胞比例，将患者分为高表达组(n=57)和低表达组(n=23)；根据Ki67表达下降水平，将患者分为明显下降组(n=66)、轻度下降组(n=14)。应用Miler and Payne(MP)治疗反应评价系统评价病理学疗效。 结果 MP治疗反应评价结果：1级8例，2级16例，3级49例，4级4例，5级3例。高表达组的病理有效率显著高于低表达组(χ2=6.218，P<0.05)，明显下降组显著高于轻度下降组(χ2=10.083，P<0.05)。 结论 Ki67可作为预测和评估乳腺癌新辅助化疗疗效的生物学指标。
[关键词] Ki67；表达；乳腺癌；新辅助化疗；关系
[中图分类号] R737.9 [文献标识码] A [文章编号] 1674-4721(2015)05(b)-0063-03
Relationship between Ki67 expression and curative effect of neoadjuvant chemotherapy for breast cancer
WU Yu-ye HUANG Mei-ling PAN Miao-jun
Department of Medical Oncology，Agribusiness Central Hospital of Guangdong Province，Zhanjiang 524000，China
[Abstract] Objective To explore the relationship between Ki67 expression and curative effect of neoadjuvant chemotherapy for breast cancer. Methods From January 2010 to January 2014，80 patients with breast cancer accepted neoadjuvant chemotherapy and treated in our hospital were selected.Patients were divided into high expression group (n=57) and low expression group (n=23) according to positive cell proportion of Ki67；patients were divided into decreased obviously group (n=64) and decreased slightly group (n=16) according to decreased level of Ki67 expression.Miler and Payne(MP)treatment reaction system was used to evaluate the curative effect of pathology. Results Evaluation result of MP treatment reaction：the number of cases in grade 1，2，3，4，and 5 was 8，16，49，4，and 3 respectively.The effective rate of pathology in high expression group was obviously higher than that of low expression group (χ2=6.218，P<0.05) and the effective rate of pathology in decreased obviously group was obviously higher than that of decreased slightly group (χ2=10.083，P<0.05). Conclusion Ki67 can be considered as a biological indicator in predicting and evaluating the curative effect of neoadjuvant chemotherapy on breast cancer.
[Key words] Ki67；Expression；Breast cancer；Neoadjuvant chemotherapy；Relationship
乳腺癌是肿瘤科临床常见病、多发病，其治疗越来越受到人们的重视。目前治疗方法多为：术前化疗-手术切除-术后化放疗，新辅助化疗(neoadjuvant chem-otherapy，NC)指术前化疗。NC能缩小肿瘤体积，还可降低区域淋巴结分期，利于患者预后。Ki67与细胞的有丝分裂有关，与染色质相连，被看作是染色体的骨架，是能反映细胞群体增殖活性较可靠的生物学指标之一[1-5]。本研究旨在寻找局部晚期乳腺癌中生物学标志物Ki67对NC的预测价值，探讨对该疾病的最佳治疗方案。
1 资料与方法
1.1 一般资料
选取本院2010年1月～2014年1月收治入院的接受NC的乳腺癌患者80例，患者年龄24～70岁，中位年龄51岁，年龄≤35岁者4例(5.0%)，>35岁者76例(95.0%)。T1期48例(60.0%)，T2期30例(37.5%)，T3期2例(2.5%)。腋窝淋巴结有转移者37例(46.2%)，无转移者43例(53.8%)。组织学级别：Ⅰ级4例(5.0%)，Ⅱ级50例(62.5%)，Ⅲ级26例(32.5%)。Ki67指数为0.9%～95.0%，平均27.8%。Ki67的阳性细胞比例≥30%者57例(71.2%)，为高表达组，<30%者23例(28.8%)，为低表达组；根据Ki67表达下降水平，将患者分为明显下降组66例(82.5%)、轻度下降组14例(17.5%)。 (吴昱冶 黄美玲 潘妙君)
[关键词] Ki67；表达；乳腺癌；新辅助化疗；关系
[中图分类号] R737.9 [文献标识码] A [文章编号] 1674-4721(2015)05(b)-0063-03
Relationship between Ki67 expression and curative effect of neoadjuvant chemotherapy for breast cancer
WU Yu-ye HUANG Mei-ling PAN Miao-jun
Department of Medical Oncology，Agribusiness Central Hospital of Guangdong Province，Zhanjiang 524000，China
[Abstract] Objective To explore the relationship between Ki67 expression and curative effect of neoadjuvant chemotherapy for breast cancer. Methods From January 2010 to January 2014，80 patients with breast cancer accepted neoadjuvant chemotherapy and treated in our hospital were selected.Patients were divided into high expression group (n=57) and low expression group (n=23) according to positive cell proportion of Ki67；patients were divided into decreased obviously group (n=64) and decreased slightly group (n=16) according to decreased level of Ki67 expression.Miler and Payne(MP)treatment reaction system was used to evaluate the curative effect of pathology. Results Evaluation result of MP treatment reaction：the number of cases in grade 1，2，3，4，and 5 was 8，16，49，4，and 3 respectively.The effective rate of pathology in high expression group was obviously higher than that of low expression group (χ2=6.218，P<0.05) and the effective rate of pathology in decreased obviously group was obviously higher than that of decreased slightly group (χ2=10.083，P<0.05). Conclusion Ki67 can be considered as a biological indicator in predicting and evaluating the curative effect of neoadjuvant chemotherapy on breast cancer.
[Key words] Ki67；Expression；Breast cancer；Neoadjuvant chemotherapy；Relationship
乳腺癌是肿瘤科临床常见病、多发病，其治疗越来越受到人们的重视。目前治疗方法多为：术前化疗-手术切除-术后化放疗，新辅助化疗(neoadjuvant chem-otherapy，NC)指术前化疗。NC能缩小肿瘤体积，还可降低区域淋巴结分期，利于患者预后。Ki67与细胞的有丝分裂有关，与染色质相连，被看作是染色体的骨架，是能反映细胞群体增殖活性较可靠的生物学指标之一[1-5]。本研究旨在寻找局部晚期乳腺癌中生物学标志物Ki67对NC的预测价值，探讨对该疾病的最佳治疗方案。
1 资料与方法
1.1 一般资料
选取本院2010年1月～2014年1月收治入院的接受NC的乳腺癌患者80例，患者年龄24～70岁，中位年龄51岁，年龄≤35岁者4例(5.0%)，>35岁者76例(95.0%)。T1期48例(60.0%)，T2期30例(37.5%)，T3期2例(2.5%)。腋窝淋巴结有转移者37例(46.2%)，无转移者43例(53.8%)。组织学级别：Ⅰ级4例(5.0%)，Ⅱ级50例(62.5%)，Ⅲ级26例(32.5%)。Ki67指数为0.9%～95.0%，平均27.8%。Ki67的阳性细胞比例≥30%者57例(71.2%)，为高表达组，<30%者23例(28.8%)，为低表达组；根据Ki67表达下降水平，将患者分为明显下降组66例(82.5%)、轻度下降组14例(17.5%)。 (吴昱冶 黄美玲 潘妙君)